Definium Therapeutics Reports Positive Phase 3 Clinical Results and Strong Cash Position for Q3 2026

Definium Therapeutics (DFTX) reported strong third-quarter 2026 results, highlighted by positive Phase 3 clinical data for its DT120 ODT candidate. The company achieved significant placebo-adjusted improvements on the HAM-A scale in both Voyage and Panorama studies for Generalized Anxiety Disorder (GAD). Additionally, the FDA granted a second breakthrough therapy designation for DT120 ODT regarding the treatment of major depressive disorder (MDD) following positive Emerge MDD results. Financially, the company has significantly strengthened its balance sheet, reporting $1.05 billion in cash and short-term investments compared to $412 million at the end of 2025. This capital position provides a projected runway into 2030. Management remains on track to submit a New Drug Application (NDA) for DT120 ODT in the first half of 2027, with preliminary commercial pricing estimated between $30,000 and $75,000 per treatment course.

11 articles from 3 sources · updated

Coverage